Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Moleculin Biotech's Annamycin?
Annamycin is a small molecule commercialized by Moleculin Biotech, with a leading Phase II program in Refractory Acute Myeloid Leukemia;Relapsed...
Annamycin by Moleculin Biotech for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Annamycin is under clinical development by Moleculin Biotech and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...
Annamycin by Moleculin Biotech for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Annamycin is under clinical development by Moleculin Biotech and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
Annamycin by Moleculin Biotech for Angiosarcoma: Likelihood of Approval
Annamycin is under clinical development by Moleculin Biotech and currently in Phase II for Angiosarcoma. According to GlobalData, Phase II...
Annamycin by Moleculin Biotech for Liposarcoma: Likelihood of Approval
Annamycin is under clinical development by Moleculin Biotech and currently in Phase II for Liposarcoma. According to GlobalData, Phase II...
Annamycin by Moleculin Biotech for Synovial Sarcoma: Likelihood of Approval
Annamycin is under clinical development by Moleculin Biotech and currently in Phase II for Synovial Sarcoma. According to GlobalData, Phase...
Annamycin by Moleculin Biotech for Soft Tissue Sarcoma: Likelihood of Approval
Annamycin is under clinical development by Moleculin Biotech and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData,...